Search Within

Connie Wing-Ching Lee Batlevi

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (26)
  2. Journal Article (5)
  3. Research Letter (1)
  4. Review (1)
Groups
  1. Center for Hematologic Malignancies (33)
  2. Department of Medicine (33)
  3. GSK Faculty (33)
  4. Hematologic Malignancies, Division of (33)
  5. Human Oncology and Pathogenesis Program (33)
  6. Lymphoma (33)

More Groups

People
  1. Andrew Zelenetz (23)
  2. Maria Palomba (21)
  3. Anas Younes (20)
  4. Matthew Matasar (20)
  5. Steven Horwitz (20)
  6. Alison Moskowitz (19)

More People

Years
  1. 2023 (3)
  2. 2022 (8)
  3. 2021 (1)
  4. 2020 (3)
  5. 2019 (5)
  6. 2018 (1)

More Years

Publications
  1. Blood (18)
  2. Blood Advances (2)
  3. Cancer Research (2)
  4. Hematological Oncology (2)
  5. Transplantation and Cellular Therapy (2)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (20)
  2. Nature Publishing Group (3)
  3. American Association for Cancer Research (2)
  4. Elsevier Inc. (2)
  5. Wiley Blackwell (2)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (33)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
    Research Letter

    Stuver, R.; Shah, G. L.; Korde, N. S.; Roeker, L. E.; Mato, A. R.; Batlevi, C. L.; Chung, D. J.; Doddi, S.; Falchi, L.; Gyurkocza, B.; more...
    Cancer Cell (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era
    Meeting Abstract

    Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • MSK-IMPACT Heme: Validation and clinical experience of a comprehensive molecular profiling platform for hematologic malignancies
    Meeting Abstract

    Ptashkin, R. N.; Benayed, R.; Ziegler, J.; Rema, A. B.; Sadowska, J.; Kiecka, I.; Ho, C.; Yao, J. J.; Moung, C.; Petrova-Drus, K.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Using genomic data for selecting the treatment of lymphoma patients
    Review

    Batlevi, C. L.; Shah, G.; Forlenza, C.; Intlekofer, A.
    Current Opinion in Hematology (2019)

    Fulltext@MSK | Save